Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) EBIT (2016 - 2026)

Tenax Therapeutics' EBIT history spans 7 years, with the latest figure at -$17.0 million for Q4 2017.

  • On a quarterly basis, EBIT rose 74.78% to -$17.0 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$9.2 million, a 85.63% increase, with the full-year FY2025 number at -$56.4 million, down 189.24% from a year prior.
  • EBIT hit -$17.0 million in Q4 2017 for Tenax Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, EBIT for TENX hit a ceiling of $4.7 million in Q2 2016 and a floor of -$67.5 million in Q4 2016.
  • Historically, EBIT has averaged -$7.3 million across 4 years, with a median of -$1.6 million in 2013.
  • The widest YoY moves for EBIT: up 245.01% in 2016, down 547.72% in 2016.
  • Tracing TENX's EBIT over 4 years: stood at -$1.2 million in 2013, then tumbled by 741.28% to -$10.4 million in 2015, then tumbled by 547.72% to -$67.5 million in 2016, then soared by 74.78% to -$17.0 million in 2017.
  • Business Quant data shows EBIT for TENX at -$17.0 million in Q4 2017, $1.3 million in Q3 2017, and $3.0 million in Q2 2017.